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SYNOPSIS     26 
Objectives: This study was focused on analysing the heterogeneity of mutations 27 
occurring in the regulators of efflux-mediated MDR in Salmonella Typhimurium. 28 
Moreover, the impact of such mutations on impairing the transcription of ramA, acrB, 29 
tolC and acrF was also assessed as was the impact on the resistance or decreased 30 
susceptibility phenotype. 31 
Methods: Strains were selected in vitro under increasing ciprofloxacin concentrations. 32 
Etest and broth microdilution tests were used to determine the MICs of several 33 
unrelated compounds. Screening of mutations in the quinolone target genes and the 34 
MDR regulators was performed. RT-PCR analysis was used to detect the levels of 35 
expression of acrB, tolC, ompF, acrF, emrB, acrR, ramA, soxS and marA.  36 
Results: All mutant strains showed increased MICs of most of the antimicrobials tested, 37 
with the exception of kanamycin. Mutations in the quinolone target genes did not occur 38 
in all the mutants, which all harboured mutations in the ramRA regulatory region. All 39 
the mutants overexpressed ramA, tolC and acrB (when active) whereas differential 40 
results were seen for the remaining genes.  41 
Conclusions: Mutations in the ramRA region related to resistance and/or decreased 42 
susceptiblity to antimicrobials predominate in Salmonella. There is heterogeneity in the 43 
type of mutations, with deletions affecting the RamR binding sites having a greater 44 
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INTRODUCTION 50 
The ever increasing levels of resistance to antimicrobial compounds are of great 51 
concern, particularly for pathogens of clinical relevance. Salmonella enterica serovar 52 
Typhimurium is a pathogen distributed worldwide which typically causes gastroenteritis 53 
in humans.1 Fluoroquinolones and cephalosporins are the current first-line treatments, 54 
however, recent data have revealed that in particular geographic areas, such as China, 55 
high percentages of resistance to compounds such as nalidixic acid (61.9%) and 56 
cefepime, cefotaxime and ceftazidime (90%) have already been detected.2 57 
 Quinolone resistance has been widely studied in Enterobacteriaceae, particularly 58 
in Escherichia coli and S. enterica.3 In E. coli the mechanism which largely contributes 59 
to resistance and/or decreased susceptibility to quinolones is the acquisition of 60 
mutations located in the genes encoding the two quinolone targets: DNA gyrase (gyrA 61 
and gyrB) and topoisomerase IV (parC and parE).4,5 These mutations are usually 62 
acquired in the quinolone resistance-determining regions (QRDRs) detected in each of 63 
the target genes.3 On the other hand, increased drug extrusion by means of the 64 
overexpression of AcrAB-TolC, the main efflux pump described in Enterobacteriaceae,3  65 
is also of great concern since it confers cross-resistance to several unrelated compounds, 66 
including antimicrobial drugs.6,7 To a lesser extent, other efflux systems, such as AcrEF 67 
and EmrAB, have been reported to participate in the extrusion of antimicrobial 68 
compounds.8,9 In Salmonella increased efflux has been described as the primary 69 
mechanism in quinolone resistance acquisition.10 Alternatively, decreased production of 70 
the OmpF porin has at times been related to the MDR phenotype11,12 despite 71 
controversial data suggesting no clear role in S. enterica.13 72 
 Several regulators have been reported to influence the expression of the acrAB 73 
operon in Salmonella. AcrR is the local repressor encoded upstream of the acrAB genes 74 
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and mutations within its coding sequence have been associated with increased 75 
expression of the pump.14 In addition, three homologous transcriptional activators, 76 
RamA, SoxS and MarA, have been associated with increased acrB and tolC expression 77 
levels. While clear associations have been reported for enhanced production of SoxS 78 
and RamA and overexpression of acrAB,11,15,16 only indirect results have associated 79 
greater production of MarA with increased levels of resistance, supposedly mediated by 80 
higher levels of AcrAB.11,17 In terms of regulation, each of these three activators has its 81 
own regulator: RamR, SoxR and MarR, respectively.3 In terms of the MDR phenotype, 82 
the clinical relevance of mutations located in the genes encoding for these latter 83 
regulators has been clearly shown for RamR,18,19 while there have been few reports for 84 
mutations located in the soxRS region.11,15 Concerning MarA, even though its 85 
overexpression has been detected in MDR S. enterica strains,8,20 the putative 86 
responsible mutations in the marRAB region have not been mapped. Naturally-occurring 87 
mutations in this region have been widely reported in E. coli,21,22 whereas, to our 88 
knowledge, such mutations in S. enterica have only been reported in a single study, 89 
associating it with high MarA overexpression and an MDR phenotype.12 90 
 The aim of this study was to determine the mechanisms involved in increasing 91 
the MICs of different antimicrobial agents in a collection of S. Typhimurium mutants 92 
selected in vitro, particularly when studying strains with low MICs of ciprofloxacin and 93 
their derivative mutants selected at the initial steps of drug exposure following a 94 
stepwise procedure. The mechanisms studied included target gene mutations and the 95 
expression of several genes involved in decreasing the intracellular concentration of the 96 
drug. Moreover, and as a novel approach, we also assessed the role and heterogeneity of 97 
ramRA mutations and their impact on increasing the expression of ramA and the 98 
phenotype of decreased susceptibility to multiple antibiotics or MDR. 99 
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MATERIALS AND METHODS 100 
Bacterial strains and selection of resistant mutants  101 
Two S. Typhimurium clinical isolates, strains 59-wt and 60-wt, were recovered from 102 
independent stool samples in the Department of Clinical Microbiology at the Hospital 103 
Clinic of Barcelona, Spain. Strain 59-wt has previously been characterised as have its 104 
derivative mutants displaying increasing ciprofloxacin MICs, including the highly 105 
resistant mutant 59-64.23 As indicated, the clinical isolate 59-wt was grown at 37ºC on 106 
MacConkey agar plates in the presence of ciprofloxacin (Fluka) in a multi-step selection 107 
process with doubling concentrations of the drug.23 Single colonies were randomly 108 
selected at different steps and previously characterised. In the present study we 109 
characterised additional randomly-selected colonies during the process (59-mut1, 59-110 
mut2 and 59-mut3) to assess the occurrence of heterogeneity in the mechanisms of 111 
resistance. Likewise, strain 60-wt was similarly treated and exposed to increasing 112 
ciprofloxacin concentrations and two different mutants were randomly selected (60-113 
mut1 and 60-mut2). 114 
 115 
Susceptibility testing  116 
The MICs of several quinolones and unrelated antimicrobial compounds were 117 
determined by Etest (AB Biodisk) according to the manufacturer’s recommendations 118 
and interpreted according to CLSI guidelines.24 The broth microdilution method was 119 
used to evaluate the MICs of ciprofloxacin, norfloxacin and nalidixic acid when 120 
maximum Etest values were reached. The compounds tested were: ciprofloxacin, 121 
norfloxacin, nalidixic acid, chloramphenicol, tetracycline, erythromycin, amoxicillin, 122 
ceftriaxone and cefoxitin.  123 
 124 
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Detection of mutations within the QRDRs and regulatory loci  125 
Mutations acquired in the QRDRs of the gyrA, gyrB, parC, and parE genes, as well as 126 
in the MDR regulatory loci soxRS, marRAB, acrR and ramR were screened by PCR 127 
amplification as described previously.25 Amplicons were purified and sent to Beckman 128 
Coulter Genomics (Essex, UK) for sequencing reactions. Detection of mutations was 129 
carried out using the BioEdit® software (Ibis Biosciences, Carlsbad, CA) by comparison 130 
with the genome of S. Typhimurium LT2 as the reference strain (RefSeq 131 
NC_003197.1). 132 
 133 
RNA extraction and real time PCR  134 
Bacterial pellets were obtained as described previously.25  Briefly, strains were grown in 135 
LB at 37ºC with shaking to reach the exponential phase (OD600=0.6). Four mL of 136 
bacterial cells were treated with 8 mL of RNA Protect Bacteria Reagent (Qiagen) and 137 
subsequently incubated with Tris-EDTA (TE) buffer supplemented with lysozyme. 138 
RNA extractions were obtained using the Maxwell ® 16 Research Instrument 139 
(Promega) and the Maxwell® 16 LEV simplyRNA Blood Kit (Promega) following the 140 
manufacturer’s recommendations. Five independent RNA extractions were made.  141 
The acrB, tolC, ompF, acrF, emrB, ramA, marA, soxS and acrR genes were 142 
tested for RT-PCR analysis following previously described conditions.26 The 16S rRNA 143 
gene was used as an internal control for normalisation, and susceptible strains 59-wt and 144 
60-wt were the reference strains for their respective derived mutants. The 2−∆∆CT method 145 
was used for relative gene expression calculations.27 Five independent assays were 146 
performed and each RNA sample was tested in triplicate. The primers used are reported 147 
in Table 1. Mean values and standard deviation are detailed in Table 2. 148 
 149 
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RESULTS AND DISCUSSION 150 
Quinolone resistance and the MDR phenotype 151 
Three and two derivative mutants were selected from the quinolone-susceptible clinical 152 
isolates 59-wt and 60-wt, respectively. Susceptibility testing to several unrelated 153 
compounds was used to determine the acquisition of the quinolone resistance and MDR 154 
phenotypes (Table 3). The term MDR has been defined as resistance to one agent in 155 
three or more antimicrobial categories,28 or to four or more antimicrobials in the 156 
particular case of nontyphoidal Salmonella.29 In the present study we used instead the 157 
term decreased susceptibility to multiple antibiotics when increased MICs to more than 158 
4 antimicrobial compounds were seen even though the resistance breakpoints were not 159 
reached. Strain 59-64, already characterised in a previous study,23 was also included in 160 
the present work for comparison with the mutants.  161 
The results showed that in comparison with their wild-type strain, all selected 162 
mutants had increased MICs (1.5- to >8-fold) to all the drugs tested, except for 163 
kanamycin, for which no increase was recorded. Only 59-wt derivative mutants showed 164 
the acquisition of QRDR mutations (Table 4). Strains 59-mut1 and 59-mut2 showed a 165 
similar genetic background in terms of target gene mutations. However, higher MIC 166 
values were seen for 59-mut2 concerning all the drugs (except for amoxicillin and 167 
chloramphenicol, which had already shown maximum Etest values in 59-wt, and 168 
tetracycline). Likewise, on comparing strains 60-mut1 and 60-mut2 a similar conclusion 169 
was obtained, with higher MIC results seen for 60-mut2 despite having background 170 
similarity. In accordance with the fact that strains 59-mut3 and 59-64 were selected at 171 
higher ciprofloxacin concentrations, these strains showed the highest MICs, mostly 172 
concerning quinolones, being maximal for strain 59-64.  173 
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 Taking into account the increased MICs of most of these compounds in all the 174 
mutants, and the fact that increased efflux confers a cross-resistance phenotype by 175 
means of increased AcrAB or even a hitherto uncharacterised efflux pump,6,23 enhanced 176 
extrusion activity was the most likely mechanism underlying this phenotype. Moreover, 177 
the results obtained from 60-wt and its derivative mutants strengthen the idea that efflux 178 
is selected at primary stages of the process of quinolone resistance acquisition as 179 
suggested previously,10,25 and this mechanism is selected even before target gene 180 
mutations. It should be noted that mutants selected in a single step-selection process, 181 
usually performed at concentrations higher than the initial MIC, may follow a different 182 
pattern of acquisition of resistance mechanisms. 183 
  184 
Expression of structural genes involved in MDR 185 
Gene expression analysis was performed to determine the expression patterns of 186 
genes related to bacterial efflux and permeability. The results were interpreted after 187 
comparison of the expression levels of each clinical isolate with their respective mutant 188 
derivatives. The genes studied were acrB, tolC, ompF, acrF and emrB (Figure 1)(Table 189 
2). Overexpression of the AcrAB-TolC efflux pump has been reported as the most 190 
relevant mechanism in terms of efflux.3 In the present study acrB was only analysed in 191 
60-wt and its derivates, which all overexpressed this gene (5.2- to 9.5-fold), since it was 192 
reported that 59-wt has a mutation inactivating the acrAB operon.23 The tolC gene was 193 
found to be consistently overexpressed in all the mutants (>2.3-fold), particularly for 194 
strains 59-mut2 and 60-mut2 (5.4- and 6.2-fold, respectively). On the contrary, ompF 195 
always showed decreased expression with the strongest results being seen in strains 59-196 
64 (-3.3-fold) and 60-mut2 (-2.4-fold). With these results we suggest that AcrAB-TolC 197 
was involved in the phenotype of decreased susceptibility to multiple antibiotics in the 198 
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case of 60-wt derivatives whereas an unknown efflux system, likely acting in 199 
conjunction with TolC, participated in the case of 59-wt derivatives. 200 
 Next, we assessed other efflux-related genes, such as acrF and emrB, (Figure 201 
1)(Table 2) which may play a secondary role in antibiotic resistance.8,9 Our results 202 
showed that only two strains clearly overexpressed acrF [59-mut2 (6-fold) and 60-mut2 203 
(4.9-fold)] whereas emrB showed a slightly decreased expression in all the mutants (-204 
1.2- to -1.9-fold). Thus, we can only suggest a role in increasing the MICs mentioned 205 
for the AcrEF efflux system in these two particular mutants, one of which is also an 206 
AcrAB-overproducer (60-mut2). 207 
 208 
Expression of the MDR regulators: the key role of ramA 209 
In addition to the analysis of these structural genes, we also studied the levels of 210 
expression of the AcrAB regulators: acrR, ramA, soxS and marA (Figure 1)(Table 2). 211 
We could not find a clear interpretation for acrR expression. In contrast, ramA was 212 
overexpressed in all the mutants thereby suggesting this regulator as the cause of the 213 
increased MICs in both the mutants overexpressing acrB and those overexpressing an 214 
unknown efflux system. Similar results have also highlighted the greater importance 215 
and prevalence of increased RamA over that of the other regulators.16,30 Maximal ramA 216 
expression levels were seen for 59-mut2 and 60-mut2 (66- and 74.2-fold, respectively) 217 
above the levels detected for the remaining mutants (13.4- to 19.6-fold). In line with 218 
these results, these two strains also showed higher MICs and acrB and tolC expression 219 
values in comparison with their closely related mutants 59-mut1 and 60-mut1, 220 
respectively. In addition, as mentioned above, 59-mut2 and 60-mut2 were also reported 221 
to clearly overexpress acrF. This latter association between high ramA expression (>60-222 
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fold in the present study) and tolC and acrF overexpression agrees with a previously 223 
reported study.31 224 
The soxS expression values detected in the present study were <2-fold higher in 225 
most of the mutants versus the expression levels seen in the two clinical isolates (Figure 226 
1). Only two mutants, strains 59-64 and 60-mut2 showed an overexpression of >4-fold. 227 
However, it was not possible to consistently associate this trait with higher expression 228 
values of ramA or acrF in both mutants. On the contrary, these two strains did show the 229 
minimum levels of ompF expression (-3.3- and -2.2-fold, respectively). Similarly, marA 230 
transcription also showed ≤2-fold increased expression in three mutant strains: 59-mut1, 231 
59-mut3 and 60-mut1. On the contrary, the highest levels were seen in 59-mut2 (4.3-232 
fold), 59-64 (3.7-fold) and 60-mut2 (3.6-fold).  233 
To understand our results it is worth mentioning that the RamA binding sites 234 
have already been reported in Salmonella concerning the acrAB and tolC promoters.32 235 
The 20-bp sequences recognised by this regulator resemble those initially reported to be 236 
present in all members of the marA/soxS/rob regulon in E. coli.33 It has been described 237 
that most of the residues of the two helix-turn-helix motifs (important for DNA 238 
sequence recognition) of MarA from E. coli are conserved in RamA from Salmonella 239 
enterica serovar Paratyphi B.34 Moreover, it has previously been reported that the 240 
marRAB promotor contains its own marbox sequence.33 In agreement with this, RamA 241 
from S. Paratyphi B has been shown to bind the MarA operator of E.coli.34 Thus, the 242 
binding sites characterised for MarA and SoxS in E. coli, equally termed marbox or 243 
soxbox, are similar to the already mentioned rambox in Salmonella.31,32 Therefore, 244 
increased levels of RamA (>60-fold) and/or SoxS (>4-fold) could bind to the 245 
rambox/marbox located in the marRAB promoter and activate marA transcription, hence 246 
explaining the increased levels of marA expression observed for strains 59-mut2 247 
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[RamA-overproducer (>60-fold)], 59-64 [SoxS-overproducer (>4-fold)] and 60-mut2 248 
[RamA-overproducer (>60-fold) and SoxS-overproducer (>4-fold)]. Nonetheless, lower 249 
ramA overexpression values (13- to 20-fold) would not have the same effect, thereby 250 
reinforcing the idea of an activator concentration-dependent response.31,35  251 
 252 
Unravelling the mutations leading to the phenotype of decreased susceptibility to 253 
multiple antibiotics  254 
In order to determine the mutations underlying the resistance phenotypes, sequencing 255 
and detection of mutations was performed in all the strains for all known regulators of 256 
MDR (acrRA, ramRA, soxRS, marRAB and acrSE). The results revealed the acquisition 257 
of mutations in the ramRA loci for all the mutants (Table 4). Mutations were located 258 
within the ramR coding sequence, either leading to a single amino acid substitution 259 
(Gln-19?Pro, strain 60-mut1) or even deletions of 44 and 6 nucleotides (strains 59-260 
mut1 and 59-mut3, respectively). Surprisingly, the two strains (59-mut2 and 60-mut2) 261 
with the highest ramA overexpression values harboured a similar genotype: a 6- and 16-262 
nucleotide deletions, respectively, in the ramA promoter. Lastly, and as previously 263 
reported23 strain 59-64 showed a single-nucleotide change also located in the ramA 264 
promoter.  265 
 Previous reports have revealed that mutations or gene interruptions can be either 266 
acquired within ramR or in the ramA promoter.11,16,30 However, no association has ever 267 
been made between the type of mutation and transcription levels of ramA. The results 268 
observed in the present study point out that severe nucleotide deletions located in the 269 
ramA promoter have a higher impact on increasing the expression of this regulator, 270 
whereas mutations within ramR or single nucleotide changes in the ramA promoter have 271 
a lesser effect. We performed an exhaustive analysis of the literature looking for studies 272 
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which determined both the ramA transcription levels and ramRA mutations in strains 273 
with resistance or decreased susceptibility to fluoroquinolones. Studies conducted in 274 
serovars Typhimurium,36,37 Enteritidis,11 Kentucky38 and other serovars30 were found to 275 
report similar results (Table 4). In order to understand this situation, it is necessary to 276 
note that RamR has been reported to bind as a homodimer to two RamR binding sites 277 
located in the ramA promoter (Figure 2).37 Thus, taking into account all this information 278 
we hypothesize that important deletions occurring in these binding sites seriously impair 279 
the RamR repressive activity by preventing RamR binding and lead to high levels of 280 
ramA expression (>60-fold). On the contrary, mutations or deletions occurring in RamR 281 
or single nucleotide modifications affecting one binding site do not seem to abolish 282 
repression to the same extent and lead to moderate levels of ramA transcription (<~40-283 
fold). This latter situation would be supported by the capacity of the mutated form of 284 
RamR to partially preserve its repressive activity or by the existence of other regulators 285 
capable of binding to the ramA promoter even in the absence of a functional RamR 286 
protein. Nonetheless, to our knowledge two exceptions have been reported, one S. 287 
Kentucky strain38 and one S. Paratyphi B mutant (Table4).30 The former situation might 288 
be explained by a large deletion detected at the very beginning of the repressor 289 
(affecting the protein sequence from the amino acid at position 14), whereas no clear 290 
explanation could justify the latter situation. Therefore, in order to elucidate the role of 291 
these mutations and strengthen or not our hypothesis, a larger number of strains needs to 292 
be analysed in further studies.  293 
 In no strain did we find any mutation in any of the other regulatory sequences 294 
analysed in the present study. Consequently, we are unable to explain the increased soxS 295 
transcription reported in 59-64 and 60-mut2. Concerning acrF overexpression, previous 296 
results have associated it with mutations within the acrS gene or in the acrEF 297 
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promoter.9 However, in the present study no mutation in the acrSE regulatory region 298 
could explain our findings. Instead, and as previously mentioned and reinforced by our 299 
results, overexpression of this efflux component is related to the levels of ramA 300 
transcription.31 High levels of ramA expression trigger acrF overexpression whereas 301 
intermediate levels do not. In line with these results, a previous study has also 302 
associated nucleotide deletions in the ramA promoter with acrEF overexpression.36 In 303 
view of these findings, the regulatory network that controls the expression of genes 304 
involved in the phenotype of decreased susceptibility to multiple antibiotics or MDR 305 
still needs further research to completely understand the bacterial response for survival 306 
under antimicrobial exposure. Nonetheless, we must keep in mind that our observations 307 
have arisen from mutants selected in a stepwise process which may harbour additional 308 
mutations with unknown influence. Additional experiments are required in order to 309 
validate these results. 310 
 311 
Conclusions 312 
The results of our study indicate that RamA overexpression leads to the 313 
phenotype of decreased susceptibility to multiple antibiotics by using two different 314 
efflux-related strategies: overexpression of AcrAB and overexpression of a hitherto 315 
uncharacterised efflux pump. Moreover, we provide further evidence of the prevalence 316 
of ramRA mutations versus other acrB regulators in the acquisition of MDR. However, 317 
heterogeneity was observed in the types of mutations acquired, which may be associated 318 
with different levels of ramA transcription. Large deletions affecting the RamR binding 319 
sites in the ramA promoter were observed in strains with higher ramA transcription 320 
levels, a trait which may account for the highest expression levels of acrB, tolC, marA 321 
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and acrF, hence related to a major contribution to the phenotype of decreased 322 
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FIGURES: 473 
Figure 1. Expression levels obtained by RT-PCR analysis. Single and double asterisks 474 
refer to high levels of ramA overexpression, 66- and 74.2-fold, respectively, which are 475 
out of scale to facilitate the visualisation of the results.  476 
 477 
 478 
Figure 2. Representative location of the RamR binding sites and the MDR-related 479 
mutations detected in the ramA promoter. White letters and grey boxes indicate the two 480 
RamR binding sites. The -35 and -10 boxes of the ramA promoter are underlined. 481 
Ellipses indicate DNA sequences not shown. The black arrow is used for the ramA 482 
transcriptional start site (+1) as well as for the initiation of translation (RamA). 483 
 484 
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TABLES: 485 
Table 1. Primers used in the RT-PCR analysis. 486 
Genes Primers Sequence 5'-3' Reference 
Internal control    
 16S rRNA 16S_RT_F GCGGCAGGCCTAACACAT 39 
  16s_RT_R GCAAGAGGCCCGAACGTC  
Structural genes    
 acrB AcrB_RT_F TTTTGCAGGGCGCGGTCAGAATAC 11 
  AcrB_RT_R TGCGGTGCCCAGCTCAACGAT  
 tolC TolC_RT_F GTGACCGCCCGCAACAAC 26 
  TolC_RT_R ATTCAGCGTCGGCAGGTGAC  
 acrF SacrF.RT.1 TACCCAGGACGACATCTCTGA 26 
  SacrF.RT.2 CACACCATTCAGACGGCTGAT  
 emrB EmrB_RT_F CCGTCGTCCTGATGACGTTA 26 
  EmrB_RT_R CCGTTCGGTATGCGTTTCAC  
 ompF SompF.RT1 GGGCGCGACTTACTACTTCAAC This study 
  SompF.RT2 TCGTTTTCGTCCAGCAGGTT  
Regulatory genes    
 acrR SacrR.RT1 AGAACGACGCCGCTTATTGA 12 
  SacrR.RT2 GCGCCTGTTGAACCACAAC  
 ramA SramA.RT1 CTCGACACCGACCAGAAGGT 12 
  SramA.RT2 GTAAAAATGCGCGTAAAGGTTTG  
 soxS SsoxS.RT1 CATATCGACCAACCGCTAAACA 12 
  SsoxS.RT2 CGAAACATCCGCTGCAAATA  
 marA SmarA.RT1 ATTCCAAATGGCACCTGCAA This study 
    SmarA.RT2 CATTTTACGGCTGCGGATGT   
 487 
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Table 2. Mean values of RT-PCR analysis obtained in five independent experiments. 488 
 489 
Strains 
Gene expression valuesa 
acrB tolC ompF acrF emrB acrR ramA soxS marA 
59-wt  ---b  1  1  1  1  1  1  1  1  
59-mut1  ---  --- 2.7 (0.59)  -1.2 (0.23) 1.7 (0.27)  -1.5 (0.13) 1.0 (0.25) 19.6 (8.05) 1.2 (0.57) 1.3 (0.23) 
59-mut2  ---  --- 6.2 (0.36)  -1.8 (0.12) 6.0 (1.43)  -1.8 (0.22)  -1.9 (0.16) 66.0 (12.68) 1.8 (1.77) 4.3 (4.13) 
59-mut3  ---  --- 2.5 (0.49)  -1.8 (0.05) 1.7 (0.27)  -1.4 (0.35) 1.0 (0.41) 17.3 (9.44) 1.7 (0.85) 2.0 (0.51) 
59-64  ---  --- 3.2 (1.11)  -3.3 (0.10) 1.4 (0.33)  -1.9 (0.27) 2.1 (1.57) 13.4 (4.71) 4.6 (2.06) 3.7 (0.48) 
60-wt 1  1  1  1  1  1  1  1  1  
60-mut1 5.2 (1.33) 2.3 (1.02)  -1.4 (0.45) 1.6 (0.86)  -1.2 (0.57)  -1.3 (0.54) 15.4 (7.78) 1.1 (0.46) 2.0 (1.10) 
60-mut2 9.5 (4.85) 5.4 (2.69)  -2.2 (0.27) 4.9 4.77  -1.6 (0.37)  -1.2 (0.49) 74.2 (30.19) 4.3 (4.28) 3.6 (2.35) 
 490 
a Values in parenthesis represent ± the standard deviation (SD). 491 
b ---, Not determined. 492 
 493 
494 
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Table 3. Susceptibility testing of all the strains and ciprofloxacin concentrations used for the selection of mutants. 495 
Strain [CIP] (mg/L) at selection 
MICs (mg/L)b 
CIP NOR NAL AMX CRO FOX TET CHL ERY KAN 
59-wt --- a 0.012 0.094 4 >256 0.094 2 64 >256 32 1.5 
59-mut1 0.06 0.125 2 32 >256 0.190 6 128 >256 128 1.5 
59-mut2 0.25 0.38 6 96 >256 0.5 12 128 >256 256 1.5 
59-mut3 2 8 16 8128 >256 0.25 4 96 >256 128 1.5 
59-64 64 256 512 8128 >256 1 96 256 >256 >256 1.5 
60-wt --- 0.016 0.094 3 1 0.032 3 3 3 32 1 
60-mut1 0.015 0.047 0.19 6 1.5 0.064 8 8 8 192 1 
60-mut2 0.03 0.094 0.38 24 3 0.125 12 12 24 >256 1 
 496 
a ---, clinical isolate not exposed to ciprofloxacin in vitro. 497 
b CIP, ciprofloxacin; NOR, norfloxacin; NAL, nalidixic acid; AMX, amoxicillin; CRO, ceftriaxone; FOX, cefoxitin; CHL, chloramphenicol; 498 
TET, tetracycline; ERY, erythromycin; KAN, kanamycin. 499 
 500 
501 
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Table 4. Mutations acquired in the quinolone target genes and the ramRA regulatory region. Comparison of the ramA transcriptional levels and 502 
regulatory mutations with previously reported mutants. 503 
Strains 




serovar Reference GyrA GyrB ParC ParE ramR/RamRc ramA promoterd 
59-wt  ---  ---  ---  ---  ---  ---  ---  --- 1 Typhimurium This study 
59-mut1  ---  --- E466D  ---  ---  --- Del C514-G557  --- 19.6 Typhimurium This study 
59-mut2  ---  --- E466D  ---  ---  ---  --- Del T-162/C-157 66.0 Typhimurium This study 
59-mut3 S83Y  --- E466D S80R  ---  --- Del A346-G352  --- 17.3 Typhimurium This study 
59-64 S83Y D87G E466D S80R F115S  ---  --- T-158A 13.4 Typhimurium This study 
60-wt  ---  ---  ---  ---  ---  ---  ---  --- 1 Typhimurium This study 
60-mut1  ---  ---  ---  ---  ---  --- Q19P  --- 15.4 Typhimurium This study 
60-mut2  ---  ---  ---  ---  ---  ---  --- Del A-174/C-159 74.2 Typhimurium This study 
Previously reported mutants 
LTL  S83F  ---  ---  ---  ---  ---  --- Del A-174/T-166 69.1 Typhimurium 
36 
BN10055 S83Y  ---  ---  ---  ---  ---  --- Del T-162/C-161e 6.6 Typhimurium 16,37 
5408-Cip D87Y  --- E466D  ---  --- V461G G25A  --- 33.7 Enteritidis 11 
 05-8560 S83F D87N  --- S80I  ---  --- Ins (1 nt) A506  --- 24.6 Kentucky 38 
 02-8141 S83F  ---  ---  ---  ---  --- Del G42-G132  --- 106.1 Kentucky 38 
 02-2818 S83F  ---  ---  ---  ---  --- Dup (4 nt) C508  --- 29.1 Kentucky 38 
5 mutant 3 D87Y  ---  ---  ---  ---  ---  --- C-157A 10.0 Paratyphi B 30 
10 mutant 2 D87Y 
 ---  ---  ---  ---  --- 
Del G520-G534; 
E160D  --- 94.8 Paratyphi B 
30 
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3 mutant 2 S83Y  ---  ---  ---  ---  --- R46P  --- 34.3 Livingstone 30 
1 mutant 2 S83Y  ---  ---  ---  ---  ---  ---   41.6 Infantis 30 
 504 
 505 
a Del, deletion. Ins, insertion. Dup, duplication  506 
b Mutations leading to the maximum ramA expression values are represented in bold.  507 
c Mutations are indicated by either the nucleotide positions deleted relative to the translation start site or the amino acid substitution. 508 
d Numbers indicate the upstream positions relative to the translation start site. 509 
e This is a 2-nucleotide deletion although only one nucleotide affects a RamR binding site. 510 
f  Maximum ramA expression values are represented in bold. 511 
 512 
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